A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

This Phase I study is testing a new drug called ALPS12 in people with extensive-stage small cell lung cancer (SCLC) — an aggressive form of lung cancer that has spread beyond the chest. The trial is in the early stages, focused on safety and finding the right dose. **You may be eligible if:** - You are older than 18 - You have been diagnosed with extensive-stage small cell lung cancer confirmed by biopsy - Your cancer has come back or progressed after at least one prior treatment - Your overall health is good (ECOG 0–1) - You have measurable disease on imaging - Your blood counts and organ function are adequate - A tumor sample (archived or fresh) is available for testing **You may NOT be eligible if:** - You are pregnant or breastfeeding - You have a history of significant autoimmune disease - You test positive for HIV - You have active hepatitis B or C - You have previously been treated with certain immune-activating drugs (anti-CD137 or anti-CD3 antibodies) Talk to your doctor to see if this trial is right for you.